Cellebrite: Product History & Inseyets Platform
Former Executive at Cellebrite
inpractise.com/articles/cellebrite-product-history-and-inseyets-platform
Cellebrite: Product History & Inseyets Platform(August 24, 2025)
Former Executive at Cellebrite
Interview Transcript
This is a snippet of the transcript.Contact Salesto get full access.
How does that impact your ability to raise prices?
The second strategy involved changing the business model. Instead of selling a license for one UFED, the model shifted to charging based on usage, value, or volume, depending on the product. For example, Premium was initially sold with a package of unlocks. You buy a package of a certain number of unlocks that you can use. So, the more you use, the more you pay.
This is a snippet of the transcript.Contact Salesto get full access.
How does that impact your ability to raise prices?
Pathfinder and Guardian have components based on users and data volume. The more users you have, the more you pay. The more investigations you run, the more data you store, the more you pay. This happens without raising the unit cost or price per se. Your price list stays the same, but you provide more value, and the customer pays more due to the increased value.
This is a snippet of the transcript.Contact Salesto get full access.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.